<DOC>
	<DOCNO>NCT03033862</DOCNO>
	<brief_summary>Platelet activation aggregation , intrinsic thrombogenicity , biomarkers ( fibrinogen , C-reactive protein , platelet endothelial cell adhesion molecule , von Willebrand factor , p-selectin ) measure compare follow implantation Bioreabsorbable Vascular Scaffolds Drug Eluting Stents .</brief_summary>
	<brief_title>Thrombogenicity Assessment Patients Treated With Bioresorbable Vascular Scaffolds</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Subject may either sex race , must &gt; 18 year age . 2 . Subjects undergo elective PCI due de novo native coronary artery lesion ( length ≤24 mm ) reference vessel diameter ≥2.5 mm ≤3.75 mm . 3 . Subject agree participate investigational invasive clinical study period 3 month follow index procedure . 4 . Subject must willing able give appropriate inform consent . 5 . The subject able read sign date informed consent document include authorization permit release personal health information approve investigator 's Institutional Review Board ( IRB ) . Hemodynamically unstable time enrollment . Concurrent anticipate treatment warfarin ( derivative , e.g. , phenprocoumon ) , oral factor Xa inhibitor , oral direct thrombin inhibitor enrollment . GPI use prior time PCI . History bleeding , evidence active abnormal bleeding . History time intracranial hemorrhage , intracranial spinal cord surgery , central nervous system tumor aneurysm . Documented sustain severe hypertension ( systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 110 mmHg ) enrollment . Severe valvular heart disease , define American College Cardiology /American Heart Association . History within 30 day enrollment invasive surgery ( mention ) , anticipate one course study participation , plan one within 1 month post dose study drug . History within 30 day enrollment TIA ischemic ( presumed thrombotic ) stroke/CVA . Known platelet count &lt; 100,000/mm3 within 30 day enrollment . Known active hepatobiliary disease , know unexplained persistent increase serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) activity two time upper limit reference range ( upper limit `` normal '' [ ↑2xULN ] ) . Any serious medical comorbidity ( e.g. , active malignancy ) subject 's life expectancy &lt; 24 month . Known current substance abuse time enrollment . Current participation study investigational therapy participation study within last 30 day . Known hypersensitivity component current investigational product . Female subject childbearing potential . Subject woman breastfeeding . Subject part staff personnel directly involve study family member investigational staff . LVEF &lt; 30 % Subject know renal insufficiency estimate GFR &lt; 30 ml/min/1.73m dialysis time screen Subject require least two lesion treatment suitable stag PCI . Moderate heavy calcification , tortuosity condition present proximal within target segment , reduce likelihood Absorb BVS XIENCE either deliver expanded lesion . Extreme angulation ( ≥90° ) proximal within target lesion . Excessive tortuosity ( ≥ two 45° angle ) proximal within target lesion . Lesion locate within distal diseased arterial graft SVG . Aortoostial lesion ( within 3 mm aorta junction ) . Lesion locate leave main artery . Lesion locate within 2 mm origin LAD LCX . Lesion involve bifurcation : side branch ≥ 2 mm diameter , side branch either ostial nonostial lesion diameter stenosis &gt; 50 % , side branch require dilatation . Target vessel contain thrombus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>